Abstract:Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH. Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality. Methods: A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators. Results: We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported. Conclusion: Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients. Renseignements de base: Le propranolol, un bêta-bloquant non sélectif, s'est révélé efficace pour maîtriser la croissance des hémangiomes infantiles compliqués. On ne dispose pas d'un protocole uniformément accepté quant à l'administration du propranolol oral contre l'hémangiome infantile. Objectif: Nous voulions faire part de notre expérience d'utilisation du propranolol pour traiter les hémangiomes infantiles problématiques et évaluer l'efficacité de cette modalité de traitement. Méthodes: On a exécuté une analyse rétrospective des dossiers de 35 enfants consécutifs qui ont été traités par une solution orale de propranolol de façon ambulatoire dans notre clinique de dermatologie/d'anomalies vasculaires. On a établi un protocole avec l'aide de nos cardiologues pédiatriques, lequel comprenait notamment un ECG et une échographie cardiaque avant le traitement. Les photographies médicales prises après 2 mois de traitement ont été évaluées par deux évaluateurs indépendants. Résultats: Nous avons traité 31 filles et 4 garçons dont l'âge médian était de 3,5 mois. On a signalé, chez 34 patients, une amélioration rapide dès les premiers jours de traitement. L'amélioration moyenne après deux mois s'élevait à 61,5 %. Aucun effet indésirable grave n'a été signalé. Conclusion: Le propranolol était efficace pour maîtriser la phase proliférative de l'hémangiome infantile problématique. Lors de notre étude, il a été bien toléré. Le traitement peut être administré de façon ambulatoire si les parents observent les directives à la lettre. Nous croyons qu'en présence d'un hémangiome infantile problématique, le traitement par le propranolol doit être administré en première intention à des patients soigneusement sélectionnés.

A novel topical nano-propranolol for treatment of infantile hemangiomas.

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

The Efficacy and Safety of Treatments for Infantile Hemangiomas: a Bayesian Network Meta‐analysis

The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis

Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

Expression of basement membrane zone antigens at the dermo-epibolic junction in organ cultures of human skin.

Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients

[Rapid regression of infantile haemangioma with 2% propranolol ointment]

Oral propranolol for the treatment of hemangiomas in high-risk infants: safety and cost analysis of outpatient-initiated therapy

Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population

Propranolol in the Treatment of Problematic Infantile Hemangioma: Review of 35 Consecutive Patients from a Vascular Anomalies Clinic

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Propranolol‐Loaded Mesoporous Silica Nanoparticles for Treatment of Infantile Hemangiomas

Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Beyond the Proliferation Phase

Continuous Delivery of Propranolol from Liposomes-in-microspheres Significantly Inhibits Infantile Hemangioma Growth

Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience

Safety of propranolol in neonates with severe infantile hemangiomas: A fourteen-year experience

Progress In The Treatment Of Infantile Hemangioma

Efficacy and Safety of Introduction Timolol Maleate by Manometer Microneedles among Infantile Hemangioma: A Retrospective Study in China